Overview
Encode provides staffing and technology services for commercial and public sectors, with a strong focus on federal and government contracts. It connects organizations with compliant, credentialed professionals to meet mission-critical needs in healthcare and government facilities, including IHS, VA, and Military Treatment Facilities, as well as private hospitals. Beyond staffing, Encode offers Staff Augmentation and Statement of Work engagements in Cybersecurity, Digital Engineering, Automation, and Data Analytics. Its goal is to connect businesses with the right talent and professionals with the right opportunities through a human-centered, client-first approach that leverages deep government and commercial experience and strict compliance.
Work here?Claim your company
Simplify's take
What believers are saying
- On September 9, 2026, Encoded closed a $275 million Series F.
- The round funds ETX101 pivotal enrollment through 2026 and expansion through age 18.
- May 2026 patient dosing and September 8 European Epilepsy updates keep momentum visible.
What critics are saying
- ETX101 remains single-asset dependent; a failed pivotal readout destroys Encoded's valuation.
- STAT reported steroid immunosuppression can blunt gene-therapy effectiveness in Encoded's Dravet trial.
- The 2025 29% layoffs showed runway pressure before the September 2026 financing.
What makes Encode unique
- ETX101 targets SCN1A+ Dravet syndrome with a one-time gene therapy, not chronic dosing.
- FDA granted Breakthrough Therapy designation on January 12, 2026, validating the program.
- Encoded owns internal GMP manufacturing, pairing pipeline control with commercial-scale production.
Help us improve and share your feedback! Did you find this helpful?